PDE5 results in increased levels of cyclic guanosine monophosphate (cGMP), the intracellular messenger which effects vasodilation by relaxation of smooth muscle in arterioles.
Production of cGMP from guanosine triphosphate (GTP) is mediated by the nitric oxide (NO) pathway. By inhibiting PDE5, sildenafil potentiates the effects of NO and increases levels of cGMP ( Diabetes is a common cause of erectile dysfunction and therefore a number of our diabetic patients will inevitably be taking sildenafil. We present a case in which a long-standing insulin-dependent diabetic patient's stable background diabetic retinopathy progressed to a proliferative state within 6 months of commencing sildenafil for erectile dysfunction.
Case report
A 59-year-old was referred to the ophthalmic clinic with a 5-week history of floaters and decreased vision in his right eye. He was a patient with a history of insulin dependent diabetes for 37 years, but no documented evidence of diabetic retinopathy until 1996. Since then only mild background diabetic retinopathy was noted. There was a history of a right sixth nerve palsy in 1998, which resolved spontaneously without sequelae. At his last clinic visit, 5 months prior to presentation, his vision was 6/6 in both eyes. His diabetic control was deemed to be good. He maintained an average blood glucose of 7 mmo1/1, and his HbAle was between 7% and 9% over the last 3 years. There was no evidence of renal impairment. His general health was good and he was not on any concomitant medication. On examination, his visual acuity was 6/18 in the right eye and 6/5 in the left. There was a mild vitreous haemorrhage in the right eye with a large neovascular frond emanating from the optic disc (Fig. 2) . The left eye revealed flat neovascularisation at the optic disc (Fig. 3) .
In view of the unusually rapid deterioration of his diabetic retinopathy, potential causes were sought. Full cardiovascular examination and carotid Doppler scans were normal. Haematological investigations including full-blood count, erythrocyte sedimentation rate, urea and electrolytes and lipid profile were all normal.
It was not until the patient attended for laser treatment that he volunteered information regarding the use of sildenafil 100 mg weekly. This was commenced shortly after his last routine ophthalmic appointment 5 months previously.
Comment
It is well recognised that 3-11 % of patients taking sildenafil experience ocular side-effects in the form of a transient bluel green tinge to their vision, increased light We suggest keeping an open mind regarding sildenafil and proliferative diabetic retinopathy, and stress the need for a detailed and accurate drug history in all cases.
Sir,
A new method of temporary tarsorrhaphy Temporary tarsorrhaphy has been in use for many years as a method of coping with transient exposure problems of the cornea or persistent epithelial defects. The standard temporary tarshorrhaphy was performed by passing a silk suture through the lid margins and tying it over a bolster, but this has been replaced by the use of a monofilament nylon suture with or without a silicone button. The latter has substantially reduced the inflammatory reaction in the lid, but the opening and closing of the suture is still a traumatic procedure for the patient. A variation Whereby tubes are sewn to the eyelid skin and the suture passed through the lumen of the tubes was described in 1993 by Rapoza et az.1 but is still an invasive procedure demanding local anaesthesia. The use of a cyanoacrylate to glue the lashes or lid margins together, published in 1991 by Eric et al? is effective, but does not allow a good examination of the cornea. The injection of botulinum toxin A to induce a protective ptosis in corneal disease, advocated in 1988 by Kirkness et al} has not been widely adopted as the ptosis is unpredictable and the toxin is expensive.
